Non-Small Cell Lung Cancer (NSCLC) Archives

Adjuvant durvalumab does not improve survival in completely resected NSCLC

Presented By

Prof. Glenwood Goss, Ottawa Hospital, Canada

Trial

Phase 3, BR.31

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 12:15

NVL-655: a promising new option in pre-treated, drug-resistant ALK-mutated NSCLC

Presented By

Dr Alexander Drilon, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 1/2, ALKOVE-1

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 12:13

Relatlimab addition benefits only a subgroup of metastatic NSCLC

Presented By

Prof. Nicolas Girard, Institut Curie, France

Trial

Phase 2, RELATIVITY-104

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 12:11

More highlights in Lung Cancer

Trial

Phase 3, MARIPOSA, MARIPOSA-2

Type

Peer-reviewed article

4 November 2024 12:08

Osimertinib significantly improves PFS in patients with unresectable stage III EGFR-mutated NSCLC

Presented By

Prof. Suresh Ramalingam, Emory School of Medicine, GA, USA

Trial

Phase 3, LAURA

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 14:30

First-line lorlatinib provides unprecedented improvement for patients with advanced ALK-positive NSCLC

Presented By

Prof. Benjamin Solomon, Peter MacCallum Cancer Centre, Australia

Trial

Phase 3, CROWN

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 14:28

Comparable benefit of video- and in-person-delivered palliative care

Presented By

Dr Joseph Greer, Harvard Medical School, MA, USA

Trial

REACH PC

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 14:25

Subcutaneous amivantamab non-inferior and more convenient than intravenous amivantamab

Presented By

Dr Natasha Leighl, Princess Margaret Cancer Centre, Canada

Trial

Phase 3, PALOMA-3

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 14:19

Selective RET inhibitor selpercatinib doubles progression-free survival in RET-mutated NSCLC

Presented By

Prof. Herbert Ho Fung Loong, Chinese University of Hong Kong, China

Trial

Phase 3, LIBRETTO-431

Conference

ESMO 2023

Type

Peer-reviewed article

19 December 2023 09:54

The importance of detecting early NSCLC

Expert

Prof. Witold Rzyman, Medical University of Gdańsk, Poland

Conference

ESMO 2023

20 November 2023 15:34

Adding pembrolizumab to perioperative chemotherapy improves EFS in early-stage NSCLC

Presented By

Prof. Heather Wakelee, Stanford University, CA, USA

Trial

Phase 3, KEYNOTE-671

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 09:44

TTFields therapy: a new treatment modality for metastatic NSCLC

Presented By

Prof. Ticiana Leal, Emory University, GA, USA

Trial

Phase 3, LUNAR

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 09:42

Adding chemotherapy to EGFR TKI does not improve OS in advanced EGFR-mutated NSCLC

Presented By

Dr Shintaro Kanda, Shinshu University, Japan

Trial

Phase 3, AGAIN

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 09:39

A pathway from air pollution to lung cancer in non-smokers identified

Presented By

Prof. Charles Swanton, University College London, UK

Conference

ESMO 2022

Type

Peer-reviewed article

16 November 2022 18:17

Promising clinical activity of tepotinib plus osimertinib in NSCLC with MET amplification after progression on first-line osimertinib

Presented By

Prof. Julien Mazières, CHU de Toulouse, France

Trial

Phase 2, INSIGHT-2

Conference

ESMO 2022

Type

Peer-reviewed article

16 November 2022 18:10

High pathological responses in borderline resectable NSCLC patients after induction with dual immunotherapy and concurrent chemoradiotherapy

Presented By

Dr Idris Bahce, Amsterdam UMC, the Netherlands

Trial

Phase 2, INCREASE

Conference

ESMO 2022

Type

Peer-reviewed article

16 November 2022 18:05

Confirmatory mediastinoscopy not needed in resectable NSCLC

Presented By

Prof. Jouke Annema, Amsterdam UMC, the Netherlands

Trial

MEDIASTrial

Conference

ERS 2022

Type

Peer-reviewed article

30 October 2022 21:30

Sugemalimab offers PFS benefits for unresectable NSCLC

Presented By

Prof. Yi-Long Wu, Guangdong Provincial People’s Hospital, China

Trial

Phase 3, GEMSTONE-301

Conference

WCLC 2022

Type

News article

23 August 2022 11:10

First results of sotorasib plus pembrolizumab in KRAS p.G12C-mutated NSCLC

Presented By

Dr Bob Li, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 1, CodeBreaK 100/101

Conference

WCLC 2022

Type

News article

23 August 2022 11:08

IMpower010: First interim OS analysis of adjuvant atezolizumab in NSCLC

Presented By

Dr Enriqueta Felip, Vall d’Hebron University Hospital, Spain

Trial

Phase 3, IMpower010

Conference

WCLC 2022

Type

News article

23 August 2022 11:02

Sub-lobar resection as new standard-of-care for cT1aN0 NSCLC?

Presented By

Dr Nasser Altorki, Weill Cornell Medicine, NY, USA

Trial

Phase 3, CALGB 140503

Conference

WCLC 2022

Type

News article

23 August 2022 10:57

NADIM: Risk of progression identified through RNA sequencing

Presented By

Ms Marta Casarrubios, Hospital Universitario Puerta de Hierro-Majadahonda, Spain

Trial

Phase 2, NADIM

Conference

WCLC 2022

Type

News article

23 August 2022 10:55

NADIM II: OS benefit of neoadjuvant nivolumab plus chemotherapy in NSCLC

Presented By

Dr Mariano Provencio, Hospital Universitario Puerta de Hierro-Majadahonda, Spain

Trial

Phase 2, NADIM II

Conference

WCLC 2022

Type

News article

23 August 2022 10:52

POSEIDON: Novel option for harder-to-treat subgroups of patients with metastatic NSCLC?

Presented By

Prof. Solange Peters, Lausanne University, Switzerland

Trial

Phase 3, POSEIDON

Conference

WCLC 2022

Type

News article

23 August 2022 10:47

Adagrasib safe and clinically active in non-small cell lung cancer

Presented By

Dr Alexander Spira, Virginia Cancer Specialists Research Institute, VA, USA

Trial

Phase 2, KRYSTAL-1

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 12:33

Long-term benefits of combined immunotherapy over chemotherapy in non-small cell lung cancer

Presented By

Prof. Julie Brahmer, Sidney Kimmel Comprehensive Cancer Center, Australia

Trial

Phase 3, CheckMate 227

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 12:29

Effect of KRAS mutations and PD-L1 expression on therapy response in non-small cell lung cancer

Presented By

Dr Oladimeji Akinboro, US Food and Drug Administration, MD, USA

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 12:26

Real-world treatment and survival in early-stage NSCLC

Presented By

Dr Howard West, City of Hope Comprehensive Cancer Center, CA, USA

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:44

Consistent efficacy of osimertinib in Chinese and global population

Presented By

Dr Jie Wang, Beijing Cancer Hospital, China

Trial

Phase 3, ADAURA

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:43

Promising efficacy of neoadjuvant osimertinib in EGFR-mutated NSCLC

Presented By

Dr Chao Lyu, Beijing Cancer Hospital, China

Trial

Phase 2, NEOS

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:43

Pro-inflammatory tumour profile predicts complete pathological response to neoadjuvant chemoimmunotherapy

Presented By

Dr Marta Casarrubios, Hospital Puerta de Hierro-Majadahonda, Spain

Trial

Phase 2, NADIM

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:41

Furmonertinib outperforms gefitinib as first-line therapy in patients with EGFR-mutated NSCLC

Presented By

Dr Yuankai Shi, National Cancer Center, China

Trial

Phase 3, FURLONG

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:41

Second-line oritinib demonstrated potential clinical benefit in advanced EGFR-mutated NSCLC

Presented By

Prof. Caicun Zhou, Shanghai Pulmonary Hospital, China

Trial

Phase 2

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:40

Updated results confirm efficacy and safety of entrectinib in patients with NTRK fusion-positive NSCLC

Presented By

Prof. Byoung Chul Cho, Yonsei Cancer Center Seoul, South Korea

Trial

Phase 1/2, ALKA-372-001, STARTRK-1, STARTRK-2

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:40

ROS1 rearrangement-targeting unecritinib is a potential new first-line strategy

Presented By

Dr Shun Lu, Shanghai Chest Hospital, China

Trial

Phase 2

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:40

Savolitinib is effective in patients with MET-mutated NSCLC

Presented By

Dr Shun Lu, Shanghai Chest Hospital, China

Trial

Phase 2

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:39

Sintilimab plus chemotherapy improves OS in treatment-naïve, stage III–IV non-squamous NSCLC

Presented By

Dr Yunpeng Yang, Sun Yat-sen University Cancer Center, China

Trial

Phase 3, ORIENT-11

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:39

Updated results of CameL-sq trial confirm benefit of camrelizumab

Presented By

Prof. Caicun Zhou, Shanghai Pulmonary Hospital, China

Trial

Phase 3, CameL-sq

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:38

No long-term benefit of adding ipilimumab to pembrolizumab in metastatic NSCLC

Presented By

Dr Delvys Rodriguez-Abreu, Universidad de Las Palmas de Gran Canaria, Spain

Trial

Phase 3, KEYNOTE-598

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:38

In concurrent CRT for stage III, unresectable NSCLC, performance status is better with proton therapy than photon therapy

Presented By

Dr Francesco Cortiula, Maastricht University Medical Center, the Netherlands

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:37

No improved prognosis for concurrent versus sequential immune checkpoint inhibition and CRT in unresectable NSCLC

Presented By

Dr Lukas Käsmann, University Hospital Munich, Germany

Trial

Phase 3

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:37

Durvalumab after sequential CRT safe in stage III, unresectable NSCLC

Presented By

Dr Marina Garassino, University of Chicago, IL, USA

Trial

Phase 2, PACIFIC-6

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:37

Immunotherapy delays deterioration in health-related quality of life in metastatic NSCLC

Presented By

Dr Edward Garon, David Geffen School of Medicine at UCLA, CA, USA

Trial

Phase 3, POSEIDON

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:36

ELCC 2022 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

ELCC 2022

19 April 2022 10:43

Robust anticancer activity of trastuzumab deruxtecan in HER2-mutated NSCLC

Presented By

Dr Bob Li, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 2, DESTINY-Lung01

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:36

Adjuvant atezolizumab lowers relapse rate in resected NSCLC

Presented By

Dr Enriqueta Felip, Vall d’Hebron Institute of Oncology, Spain

Trial

Phase 3, Impower010

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:35

TCR clonality predicts pembrolizumab response in NSCLC

Presented By

Dr Afef Abed, Edith Cowan University, Australia

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:31

ESMO 2021 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Trial

DESTINY-Breast03, MONALEESA-2, KEYNOTE-716, CASPIAN, CheckMate-649, Impower010

Conference

ESMO 2021

4 October 2021 09:27

WCLC 2021 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

WCLC 2021

29 September 2021 11:21

Baseline CD8+ T-cells predict NSCLC immunotherapy safety

Presented By

Prof. Kan Wu, Zhejiang University School of Medicine, China

Conference

WCLC 2021

Type

News article

21 September 2021 15:26

Genomic profiling of NSCLC may be predictive of immunotherapy response

Presented By

Dr Marcelo Negrao, MD Anderson Cancer Center, TX, USA

Conference

WCLC 2021

Type

News article

21 September 2021 15:26

New preoperative classification scheme proposed for oligometastatic NSCLC

Presented By

Dr Luca Bertolaccini, European Institute of Oncology, Italy

Conference

WCLC 2021

Type

News article

21 September 2021 15:26

Discrepancies and lack of guideline adherence in EGFR+ NSCLC treatment

Presented By

Ms Ivy Elkins, EGFR Resisters, USA

Conference

WCLC 2021

Type

News article

21 September 2021 15:25

Atezolizumab promising for treating NSCLC brain metastases

Presented By

Prof. Ernest Nadal, Catalan Institute of Oncology, Spain

Trial

Phase 2, ATEZO-BRAIN

Conference

WCLC 2021

Type

News article

21 September 2021 13:24

Pembrolizumab shows potential in TKI-resistant EGFR+ NSCLC, not ALK+

Presented By

Prof. Shirish Gadgeel, University of Michigan, USA

Conference

WCLC 2021

Type

News article

21 September 2021 13:24

Real-world data shows inferior survival compared with IMpower150 results

Presented By

Dr Samantha Dean, Austin Health, Australia

Trial

Phase 3, IMpower150

Conference

WCLC 2021

Type

News article

21 September 2021 13:23

NSCLC metastases also benefit from nivolumab + ipilimumab + chemo

Presented By

Prof. David Carbone, Ohio State University, USA

Trial

Phase 3, CheckMate 9LA

Conference

WCLC 2021

Type

News article

21 September 2021 13:23

Neoadjuvant nivolumab plus chemotherapy improves surgical outcomes in NSCLC

Presented By

Dr Jonathan Spicer, McGill University, Canada

Trial

Phase 3, CheckMate 816

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 23:59

Immune-related adverse events are associated with efficacy of atezolizumab in patients with advanced NSCLC

Presented By

Dr Mark Socinski, AdventHealth Cancer Institute, FL, USA

Trial

Phase 3, IMpower130, IMpower132, IMpower150

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 22:02

Sustained efficacy of nivolumab/ipilimumab plus 2 cycles of chemotherapy in NSCLC

Presented By

Prof. Martin Reck, Lung Clinic Grosshansdorf, Germany

Trial

Phase 3, CheckMate 9LA

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 22:00

Patritumab deruxtecan (HER3-DXd) in EGFR TKI-resistant NSCLC

Presented By

Dr Jänne Pasi, Dana Farber Cancer Institute, MA, USA

Trial

Phase 1

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 20:08

Durvalumab after chemoradiation proven safe in elderly NSCLC patients

Presented By

Dr. Adrian Sacher, Princess Margaret Cancer Centre, Toronto, ON, Canada

Journal

Physician's Weekly

Conference

ASCO 2021

6 August 2021 12:21

Doubling overall survival in US veterans with stage 3 non-small cell lung cancer

Presented By

Dr. Nithya Ramnath, University of Michigan

Trial

PACIFIC

Journal

Physician's Weekly

Conference

ASCO 2021

6 August 2021 12:17

5-year PACIFIC data hold strong in NSCLC

Presented By

Dr. Camille Hertzka, AstraZeneca

Trial

Phase 3, PACIFIC

Journal

Physician's Weekly

Conference

ASCO 2021

6 August 2021 12:05

Early-Stage NSCLC: Promising Data for Neoadjuvant Durvalumab With Stereotactic Body Radiotherapy

Presented By

Dr Nassar Altorki, New York Presbyterian-Weill Cornell Medical Center, New York, USA

Journal

Physician's Weekly

Conference

ASCO 2021

6 August 2021 11:29

Novel imaging biomarkers predict benefit in stage 3 NSCLC treated with chemoradiation and durvalumab

Presented By

Dr. Khalid Jazieh, Cleveland Clinic, Ohio, USA

Journal

Physician's Weekly

Conference

ASCO 2021

6 August 2021 11:24

Phase III ADAURA Trial: CNS Recurrences slashed for NSCLC

Presented By

Prof. Roy Herbst, Yale Cancer Center, USA

Trial

Phase 3, ADAURA

Journal

Physician's Weekly

Conference

ESMO Virtual Congress 2020

18 April 2021 14:59

Atezolizumab with SABR for high-risk early-stage NSCLC: initial results

Presented By

Prof. Arta Monjazeb & Prof. Karen Kelly, UC Davis

Journal

Physician's Weekly

Conference

ASCO 2020

13 April 2021 18:56

4-year PACIFIC data hold strong in NSCLC

Presented By

Dr. Camille Hertzka , AstraZeneca

Trial

Phase 3, PACIFIC

Journal

Physician's Weekly

Conference

ESMO Virtual Congress 2020

13 April 2021 18:31

Amivantamab/lazertinib benefits patients with EGFR-mutated NCSLC

Presented By

Prof. Byoung Chul Cho, Yonsei Cancer Centre, Yonsei University College of Medicine in Seoul, South Korea

Trial

CHRYSALIS, MARIPOSA

Journal

Physician's Weekly

Conference

ESMO Virtual Congress 2020

13 April 2021 15:40

Preoperative immunotherapy in early stage NSCLC safe and feasible

Conference

ESMO 2020

Type

Peer-reviewed article

25 November 2020 15:07

No advantage of post-operative radiotherapy in patients with stage IIIA N2 NSCLC

Conference

ESMO 2020

Type

Peer-reviewed article

25 November 2020 15:06

Adjuvant osimertinib in NSCLC reduces risk of CNS recurrence

Conference

ESMO 2020

Type

Peer-reviewed article

25 November 2020 15:05

Lorlatinib outperforms crizotinib in ALK-positive advanced NSCLC

Conference

ESMO 2020

Type

Peer-reviewed article

25 November 2020 15:02

First-line immune checkpoint inhibition in metastatic NSCLC

Conference

ESMO 2020

Type

Peer-reviewed article

25 November 2020 15:00

PD-L1 density, a new predictive biomarker in NSCLC

Conference

ESMO 2020

Type

Peer-reviewed article

25 November 2020 14:59

Atezolizumab/bevacizumab for non-squamous NSCLC with high PD-L1 expression

Conference

ESMO 2020

Type

Peer-reviewed article

25 November 2020 14:58

Higher thrombotic risk in NSCLC patient with ALK rearrangement

Presented By

Dr Hanny Al-Samkari, Massachusetts General Hospital, USA

Conference

ISTH 2020

Type

Peer-reviewed article

8 September 2020 14:41

Adjuvant osimertinib in NSCLC: practice changing ADAURA trial

Presented By

Prof. Roy S. Herbst, Yale Cancer Center, USA

Trial

Phase 3, ADAURA

Conference

ASCO 2020

8 September 2020 13:39

Thoracic cancers versus COVID-19

Presented By

Leora Horn, Vanderbilt-Ingram Cancer Center, USA

Trial

TERAVOLT

Conference

ASCO 2020

28 August 2020 14:50

Cancer treatment with checkpoint inhibitors in RA patients?

Presented By

Dr Sabina Sandigursky, New York University Langone Medical Center, USA

Conference

ACR 2019

Type

Peer-reviewed article

4 February 2020 11:13

Fever during immunotherapy for NSCLC associated with shorter PFS

Presented By

Dr Osamu Kanai, Kyoto Medical Centre, Japan

Conference

ERS 2019

Type

Peer-reviewed article

28 November 2019 23:18

NSCLC: A new way to evaluate hilar and mediastinal lymph nodes

Presented By

Dr Jaume Bordas-Martínez, , Bellvitge Universitary Hospital, Catalonia, Spain

Conference

ERS 2019

Type

Peer-reviewed article

28 November 2019 20:22

Mixed data: AMG 510 in tumours with KRASG12C

Presented By

Prof. Ramaswamy Govindan, Washington University, St Louis, USA

Conference

ESMO 2019

Type

Peer-reviewed article

26 November 2019 23:30

Ceritinib in ALK+ NSCLC brain metastases

Presented By

Dr Laura Quan Man Chow, University of Texas at Austin, USA

Trial

Phase 2, ASCEND-7

Conference

ESMO 2019

Type

Peer-reviewed article

26 November 2019 23:28

Frontline ipilimumab/nivolumab improves OS in advanced NCLSC

Presented By

Prof. Solange Peters, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

Trial

Phase 3, CheckMate-227

Conference

ESMO 2019

Type

Peer-reviewed article

26 November 2019 22:05

First-line osimertinib significantly lengthens OS in NSCLC

Presented By

Prof. Suresh Ramalingam, Emory University, Atlanta, USA

Trial

Phase 3, FLAURA

Conference

ESMO 2019

Type

Peer-reviewed article

26 November 2019 21:05

Liquid biopsy to decide the best treatment for NSCLC

Presented By

Dr Shirish Gadgeel, University of Michigan, USA

Trial

Phase 2, BFAST

Conference

ESMO 2019

Type

Peer-reviewed article

26 November 2019 14:05

Tumour mutation score is a better predictor than TMB

Conference

WCLC 2019

Type

Peer-reviewed article

8 November 2019 23:42

First-line pembrolizumab monotherapy offers durable OS benefit vs chemotherapy in NSCLC patients with high PD-L1 expression

Presented By

Dr Martin Reck, Lung Clinic Grosshansdorf, Germany

Trial

KEYNOTE-024

Conference

WCLC 2019

Type

Peer-reviewed article

8 November 2019 23:23

Older age and low neutrophilia inflammation predictor for osimertinib efficacy

Conference

WCLC 2019

Type

Peer-reviewed article

8 November 2019 23:19

BMI and age do not influence survival/irAEs in patients treated with immune checkpoint inhibitors

Conference

WCLC 2019

Type

Peer-reviewed article

8 November 2019 23:14

Five-fold increase of OS at 5 years with nivolumab vs docetaxel

Presented By

Prof. Scott Gettinger, Yale Cancer Center, USA

Trial

CheckMate 017, CheckMate 057

Conference

WCLC 2019

Type

Peer-reviewed article

8 November 2019 23:00

pTMB is a feasible predictive biomarker for chemoimmunotherapy

Conference

WCLC 2019

Type

Peer-reviewed article

8 November 2019 21:58

Longer OS with atezolizumab + carboplatin + nab-paclitaxel in advanced squamous NSCLC

Trial

Phase 3, IMpower 131

Conference

WCLC 2019

Type

Peer-reviewed article

8 November 2019 21:25

Nivolumab + ipilimumab safe first-line treatment for NSCLC patients with comorbidities

Presented By

Dr Fabrice Barlesi, Hôpitaux de Marseille, France

Trial

Phase 4, CHECKMATE-817

Conference

WCLC 2019

Type

Peer-reviewed article

8 November 2019 21:15

Promising phase 1 results of novel KRAS-inhibitor in NSCLC

Presented By

Dr Ramaswamy Govindan, Washington University School of Medicine, USA

Conference

WCLC 2019

Type

Peer-reviewed article

8 November 2019 20:59

Selpercatinib (LOXO-292) shows durable activity in RET fusion-positive lung cancer

Presented By

Dr Alexander Drilon, Memorial Sloan Kettering Cancer Center, USA

Trial

LIBRETTO-001

Conference

WCLC 2019

Type

Peer-reviewed article

8 November 2019 19:01

High need for biomarkers for stage III lung cancer

Conference

WCLC 2019

Type

Peer-reviewed article

8 November 2019 18:03

EGFR TKI retreatment effective after earlier discontinuation

Conference

WCLC 2019

Type

Peer-reviewed article

8 November 2019 09:20

Neoadjuvant nivolumab/ipilimumab shows promise in resectable NSCLC

Presented By

Dr Tina Cascone, University of Texas MD Anderson Cancer Centre, USA

Trial

NEOSTAR

Conference

ASCO 2019

Type

Peer-reviewed article

15 July 2019 23:59

Overcoming the challenges of immunotherapy in non–small cell lung cancer

Presented By

Dr Sarah B. Goldberg, Dr Melissa Lynne Johnson, Dr Alexander Chi

Trial

PACIFIC, KEYNOTE-024, KEYNOTE-189

Conference

ASCO 2019

Type

Peer-reviewed article

15 July 2019 22:04

Pembrolizumab monotherapy leads to 5-year survival in some patients with NSCLC

Presented By

Dr Edward B. Garon, David Geffen School of Medicine, USA

Trial

Phase 1, KEYNOTE-001

Conference

ASCO 2019

Type

Peer-reviewed article

15 July 2019 20:17

First-in-human study shows IL1RAP-targeting drug safe in solid tumours

Presented By

Dr Ahmad Awada, Institut Jules Bordet, Belgium

Conference

ASCO 2019

Type

Peer-reviewed article

15 July 2019 13:58

Early results from TAK-788 in NSCLC with EGFR exon 20 insertions

Presented By

Dr Gregory Riely, Memorial Sloan Kettering Cancer Centre, USA

Conference

ASCO 2019

Type

Peer-reviewed article

15 July 2019 13:31

Osimertinib and RET inhibitor BLU-667 in an EGFR-mutant patient with acquired RET rearrangement

Conference

WCLC 2018

Type

Peer-reviewed article

21 November 2018 23:51

Patient-reported outcomes of first-line nivolumab + ipilimumab in high tumour mutational burden advanced non-small-cell lung cancer

Trial

Phase 3, CheckMate 227

Conference

WCLC 2018

Type

Peer-reviewed article

21 November 2018 23:44

PD-L1 expression in untreated EGFR-mutant non-small-cell lung cancer and response to osimertinib

Presented By

Prof. Suresh Ramalingam, Emory University School of Medicine, Winship Cancer Institute, USA

Trial

Phase 3, FLAURA

Conference

WCLC 2018

Type

Peer-reviewed article

21 November 2018 23:21

Next generation immunotherapy in non-small-cell lung cancer

Presented By

Prof. Solange Peters, Lausanne University Hospital and Ludwig Institute, Switzerland

Conference

WCLC 2018

Type

Peer-reviewed article

21 November 2018 23:02

Central nervous system activity of ramucirumab + osimertinib in patients with advanced T790M-positive EGFR-mutant non-small-cell lung cance

Conference

WCLC 2018

Type

Peer-reviewed article

21 November 2018 22:53

Avelumab vs docetaxel for previously treated advanced non-small-cell lung cancer

Trial

Phase 3, JAVELIN Lung 200

Conference

WCLC 2018

Type

Peer-reviewed article

21 November 2018 22:46

Potential for brigatinib as a first-line treatment option for ALK+ non-small-cell lung cancer

Presented By

Dr Ross Camidge, University of Colorado Cancer Center, USA

Trial

Phase 3, ALTA-1L

Conference

WCLC 2018

Type

Peer-reviewed article

21 November 2018 22:31

Accumulation of concomitant mutations involved in drug resistance in sequential ALK TKI treatments of ALK-positive NSCLC

Conference

WCLC 2018

Type

Peer-reviewed article

21 November 2018 22:24

Combination therapies: Where are we in 2018?

Presented By

Prof. Martin Reck, German Center for Lung Research, Germany

Conference

WCLC 2018

Type

Peer-reviewed article

21 November 2018 22:05

Entrectinib treatment in patients with ROS1+ NSCLC

Trial

STARTRK-2, STARTRK-1, ALKA-372-001

Conference

WClC 2018

Type

Peer-reviewed article

21 November 2018 21:57

Effects of dose modifications on safety and efficacy of dacomitinib for EGFR-mutant non-small-cell lung cancer

Trial

Phase 3, ARCHER 1050

Conference

WCLC 2018

Type

Peer-reviewed article

21 November 2018 21:49

Crizotinib-treated ALK IHC-positive advanced NSCLC is associated with an unfavourable prognosis when FISH negative

Conference

WCLC 2018

Type

Peer-reviewed article

21 November 2018 21:28

Choice of taxane and addition of pembrolizumab for metastatic squamous non-small-cell lung cancer

Presented By

Prof. Balazs Halmos, Albert Einstein College of Medicine and Montefiore Medical Center, USA

Trial

Phase 3, KEYNOTE-407

Conference

WCLC 2018

Type

Peer-reviewed article

21 November 2018 21:18